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The landmark study by Temel et al, of early referral to palliative
care (i.e., best supportive care (BSC)) plus standard oncology care
vs standard oncology care alone, gained widespread attention for
its demonstration of improved survival and quality of life among
lung cancer patients who received palliative care in addition to
standard oncology care (Temel et al, 2010). As the study was not
powered for survival as the primary outcome, these results—
though undeniably exciting—require confirmation in subsequent
studies. The findings are not likely to represent a type I error,
given that this experimental design supports earlier observational
population-based studies (Connor et al, 2007).
Equally important, though less touted than survival and quality-
of-life impact, is this study’s design, which bears operational,
funding, and practice implications for all cancer clinical trials
using BSC as a control arm (Zafar et al, 2008; Cherny et al, 2009;
Temel et al, 2010). For years, many cancer clinical trials have been
designed to evaluate the benefits of novel anti-cancer drugs against
BSC; many drugs have been registered based on modest survival
advantages when compared with BSC. Universally across these
studies, however, BSC control arms have not been standardised in
clinical trials; are not consistent with contemporary palliative care
practice; are not based on the extensive best available evidence
(Tieman et al, 2008); and are not described in sufficient detail to
reproduce in subsequent studies. In research reported before
the Temel paper in the New England Journal of Medicine, BSC was
a flimsy label rather than denoting a reliable, consistently applied,
replicable, or meaningful palliative care comparator for anti-
cancer interventions.
What happens when clinical trials do not standardise BSC
based on widely published, evidence-based supportive and
palliative care, or when they do not carefully delineate what
constitutes their BSC arm? The clinical care provided in the BSC
arms of cancer clinical trials is haphazard; study results are
difficult to interpret or misleading at worst and hard to generalise
at best. For example, across studies that include a BSC arm,
participants do not receive consistent symptom and needs
assessment, nor consistent, ongoing, biopsychosocial nor clinical
support. Results from one study, then, cannot be compared with
another and, without a standardised backdrop for comparison,
clinicians cannot know what to expect as results for a particular
patient. The issues raised by differences in BSC across studies are
magnified in multi-site randomised trials, where the composition
of BSC practice is left to local discretion and practice. This
heterogeneity of control arms stands in sharp contrast to the
usual rigour of intervention arms, and indeed to all other aspects
of clinical trials, wherein design elements such as chemotherapy
dose, cycle, and dose modification are carefully standardised
between collaborating sites, reported in publications, and evidence
based.
Models to codify best supportive and palliative care are available
for use in designing clinical trials, implementing studies across
sites, and reporting results (Currow et al, 2009). Nonetheless,
descriptions of BSC arms presented in the medical literature
remain consistently poor (Zafar et al, 2008; Cherny et al, 2009).
Temel’s study utilises an evidence-based definition of palliative
care, mandates documentation, and thereby demonstrates the
reproducible benefits of evidence-based BSC. Because of this
transparency, results can be translated into clinical practice. By
showing a survival advantage when early palliative care—carefully
standardised and documented—accompanies standard oncology
care, the findings of Temel et al immediately challenge the survival
impact claimed by cancer trials that incorporate non-standardised
BSC as a surrogate for evidence-based supportive and palliative
care. The quality of those previous studies pales in comparison
with that of the Temel trial, and their results are, correspondingly,
questionable. In describing a BSC arm, implementing it as a
standardised intervention, and conducting seminal comparative
effectiveness research on its introduction into clinical care,
Temel et al have set a new benchmark for BSC—a groundbreaking
contribution.
Recognition of this advance should lead to a profound change.
With a new standard for research design in cancer clinical
trials, institutional review boards (IRBs, Ethics Committees), the
Food and Drug Administration (FDA and the equivalent agencies
internationally), research funders, and journal editors should no
longer accept studies that compare interventions with ‘BSC’ that is
non-standardised, inconsistent with contemporary practice, not
evidence based, nor poorly described.
The paper by Temel et al highlights the poor quality of the
control arm of many published studies. Given this concern, it is
of immediate importance to patients and funders that rigorous *Correspondence: Dr DC Currow; E-mail: david.currow@flinders.edu.au
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marginal survival advantages demonstrated in studies of many
recently registered anti-neoplastic therapies where BSC has been
the control arm are being widely reproduced in clinical practice.
When clinical decisions in real-world settings are based on trials in
which half of all participants received suboptimal care (BSC) in
comparison with the BSC benchmark set by Temel et al, patients
may not realise the net clinical benefit, including the survival
advantage that studies suggest.
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